HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Detorubicin--an active anthracycline in untreated metastatic melanoma.

Abstract
A phase II study of detorubicin, the semisynthetic 14-diethoxyacetoxy ester of daunorubicin, was conducted in 42 patients with metastatic melanoma. The drug was administered in a dose range of 120 to 180 mg/m2 and repeated at 3-week intervals. One clinical complete remission (soft tissue) and seven partial responses (three visceral and four soft tissue) were observed among the 22 patients who had undergone no prior chemotherapy, a complete and partial response rate of 36%. The duration of response varied from 2 to 27 months with a median of 10 months. There were also four (19%) minor responses (one visceral and three soft tissue). In contrast, among the 20 patients who had undergone prior chemotherapy treatment, only three patients showed a minor response. General toxicities were acceptable and were similar to those of Adriamycin (Adria Laboratories, Columbus, Ohio). Cardiac toxicity was evaluated by cardiac biopsy and radionuclide scan. Cardiac biopsy changes were identical to those observed with Adriamycin and were progressive with cumulative dose. One patient had a high-grade biopsy at a cumulative detorubicin dose of 1,420 mg/m2. Similarly, a trend of decreasing ejection fraction with cumulative dose was noted. Only one patient developed congestive heart failure at a cumulative dose of 1,290 mg/m2, that was well compensated with digoxin and diuretics. In contrast to Adriamycin, detorubicin has shown activity in previously untreated patients with metastatic melanoma.
AuthorsS P Chawla, S S Legha, R S Benjamin
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 3 Issue 11 Pg. 1529-34 (Nov 1985) ISSN: 0732-183X [Print] United States
PMID4056844 (Publication Type: Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • detorubicin
  • Daunorubicin
Topics
  • Adult
  • Aged
  • Antibiotics, Antineoplastic (adverse effects, therapeutic use)
  • Daunorubicin (adverse effects, analogs & derivatives, therapeutic use)
  • Drug Evaluation
  • Electrocardiography
  • Female
  • Heart (drug effects, physiopathology)
  • Heart Diseases (chemically induced)
  • Humans
  • Leukopenia (chemically induced)
  • Lung Neoplasms (secondary)
  • Lymphatic Metastasis
  • Male
  • Melanoma (drug therapy, secondary)
  • Middle Aged
  • Myocardial Contraction (drug effects)
  • Skin Neoplasms (secondary)
  • Stroke Volume (drug effects)
  • Thrombocytopenia (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: